No controlled research has tested the KLOW blend for 16 weeks or shown that this duration is appropriate
These include: Persistent fatigue, cold intolerance, or constipation (suggesting hypothyroidism) Excessive thirst, increased urination, or blurred vision (indicating poor glycaemic control) Abdominal pain, nausea, or vomiting (potential pancreatitis, a rare but serious adverse effect) Right upper quadrant pain, jaundice, pale stools, or dark urine (possible gallbladder disease, which has increased risk with GLP-1 receptor agonists) [1] [2] New visual symptoms including floaters or blurred vision (potential diabetic retinopathy complications) Mood changes, particularly low mood or increased anxiety New or worsening oedema in the legs, ankles, or face Lack of expected weight loss after three to six months at therapeutic doses should also prompt discussion with your healthcare provider
Mg deficiency is common in the general population and has been associated with impaired thyroid function, metabolic disorders, and carcinogenesis
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%)
You will inject this medication under your skin in the stomach, thigh, or upper arm
